Skip to Main Content
Contribute Try STAT+ Today

Vertex Pharmaceuticals will promote Reshma Kewalramani, its chief medical officer, to president and CEO on April 1, the company announced Thursday morning. She will succeed Jeffrey Leiden, who said he would step down as president and CEO after seven years in those roles.

Leiden, who has also served as chairman, will become executive chairman, a position he will hold through the first quarter of 2023.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Symkevi

    What is Symkevi?

    Like Orkambi, which combines ivacaftor with lumacaftor, this new, dual combination therapy ​(brand name Symkevi) uses two drugs together in one treatment. Symkevi combines ivacaftor with new drug compound tezacaftor. The treatment has been tested on people with CF with two copies of the F508del mutation and those with one copy of F508del and another mutation that has residual function. The results have been positive.
    How have studies progressed?

    Two global Phase III trials have revealed that Symkevi could reduce the effects of cystic fibrosis on people with two copies of the F508del mutation and present significant improvements for those with one F508del and one ‘residual function’ mutation.
    EVOLVE study

    The EVOLVE study, which involves those with two copies of the F508del mutation found that the treatment was more stable than Orkambi, with similar benefits of around 4% lung function improvement and fewer side effects.
    EXPAND study

    The EXPAND study, which involves those with one F508del and one residual function mutation found an average absolute improvement
    I’ve made a petition – will you sign it?
    Click this link to sign the petition:

  • Pricing for drugs that were developed with public funds (NIH, charitable foundations) should be priced accordingly, not hiding under the shield of “oh these drugs cost sooooo much to develop and bring to market”.

Comments are closed.